Drug Profile
Datopotamab deruxtecan - Daiichi Sankyo
Alternative Names: Dato-DXd; DS 1062a; DS-1062; S-1062a; TROP2-directed ADCLatest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Daiichi Sankyo Company; Merck & Co
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration HER2 negative breast cancer; Non-small cell lung cancer
- Phase III Triple negative breast cancer
- Phase II Solid tumours
- Phase I/II Gastric cancer; Urogenital cancer
- No development reported Breast cancer
Most Recent Events
- 10 Apr 2024 AstraZeneca in collaboration with Daiichi Sankyo plans a phase III TROPION-Lung10 trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy, First-line therapy) in Australia, Austria, Brazil, Canada, Germany, Hungary, Italy, Japan, Poland, South Korea, Spain, Taiwan, Turkey and UK in April 2024 (IV) (NCT06357533)
- 09 Apr 2024 AstraZeneca plans a phase III TROPION-Lung14 trial for Non-small Cell Lung Cancer (Combination therapy, Late-stage disease, Metastatic disease, First line therapy, Recurrent) in Australia, China and Taiwan in May 2024 (PO) (NCT06350097)
- 02 Apr 2024 Preregistration for HER2-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) before April 2024